The Interaction of Botrocetin with Normal or Variant von Willebrand Factor (Types IIA and IIB) and Its Inhibition by Monoclonal Antibodies that Block Receptor Binding.

Yoshihiro Fujimura(Japanese Red Cross Society, Japan), Koiti Titani(Gifu Pharmaceutical University), Yoshiko Usami(University of Massachusetts Chan Medical School), Hiromu Fukui(National Archives and Records Administration), Masahiko Katayama(Takara (Japan)), Akira Yoshioka(Kyoto University), Sachiyo Nishida(National Blood Transfusion Service), Masahiro Kaneda(Tokyo University of Agriculture and Technology), S Miura(Nara Medical University), Shigeki Miyata(Japanese Red Cross Society, Japan)
Institutional Repositories DataBase (IRDB)
June 30, 1993
Cited by 0

Related Papers

SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef
|Nature|2015|466
Human Recombinant DNA–Derived Antihemophilic Factor (Factor VIII) in the Treatment of Hemophilia A
|New England Journal of Medicine|1990|266
Structural Basis for Budding by the ESCRT-III Factor CHMP3
|Developmental Cell|2006|254
Binding of human xanthine oxidase to sulphated glycosaminoglycans on the endothelial-cell surface
|Biochemical Journal|1993|213
Release of autoinhibition converts ESCRT-III components into potent inhibitors of HIV-1 budding
|Proceedings of the National Academy of Sciences|2006|182